Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

<p>amino acid sequences of mAbs in this study</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Yuncheng Bei (16546095) (author)
Diğer Yazarlar:	Jian He (16546098) (author), Xuhui Dong (16546101) (author), Yuxin Wang (16546104) (author), Sijie Wang (16546107) (author), Wan Guo (16546110) (author), Chengjie Cai (16546113) (author), Zhiye Xu (16546116) (author), Jia Wei (11469308) (author), Baorui Liu (15134681) (author), Nan Zhang (16546119) (author), Pingping Shen (16546122) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Computational Methods Database resources Drug Targets Cell surface receptor drug targets Preclinical Models Xenograft models
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Yazar:: Sheheryar Kabraji (15050565)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Yazar:: Amr El Zawily (14851115)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Yazar:: Santiago Duro-Sánchez (14959182)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Yazar:: Niklas Klümper (15048887)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Yazar:: Niklas Klümper (15048887)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yazar:: Yuanqing Ma (15052437)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_bhc8afna7418s4m6rl9ni92u6e